Royal Capital Wealth Management’s Anavex Life Sciences AVXL Stock Holding History

Royal Capital Wealth Management’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-18,500	Closed	-$191K	–	99
2022 Q3	$191K	Hold	18,500	–	–	0.22%	83
2022 Q2	$185K	Buy	18,500 +400	+2%	+$3.79K	0.2%	91
2022 Q1	$223K	Buy	18,100 +1,600	+10%	+$19.7K	0.22%	92
2021 Q4	$286K	Buy	+16,500	New	+$313K	0.28%	81

Other funds holding AVXL

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

Royal Capital Wealth Management's AVXL Position: Q4 2022 in Review

Royal Capital Wealth Management sold out of Anavex Life Sciences (AVXL) in Q4 2022, closing a stake of 18,500 shares — an estimated $191K sold.

Royal Capital Wealth Management first reported a position in AVXL in Q4 2021 and held it in 4 quarters. The position peaked at $286K in Q4 2021. 139 funds tracked by Wall St. Rank hold AVXL as of Q4 2022.

Royal Capital Wealth Management reported no remaining Anavex Life Sciences position as of Q4 2022 after selling out during the quarter.
Royal Capital Wealth Management sold 18,500 Anavex Life Sciences shares in Q4 2022, an estimated $191K.
Royal Capital Wealth Management first reported a position in Anavex Life Sciences in Q4 2021 and held it in 4 quarters.
Royal Capital Wealth Management's Anavex Life Sciences position peaked at $286K in Q4 2021.
139 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q4 2022.

Based on Royal Capital Wealth Management's 13F filing for Q4 2022, filed 14 Feb 2023.